Pfizer Earnings Top Q3 Views

Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter.
Pfizer Beats Q3 Forecasts, Raises Guidance As Activist Investor Calls For Change
Pfizer’s third-quarter revenue and adjusted profit exceeded expectations, driven by strong sales of its Covid vaccine and Paxlovid antiviral pill. Pfizer raised its full-year EPS guidance and revised revenue projections.
Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ago, beating the consensus of $0.62. The U.S. drugmaker reported sales of $17.
Pfizer’s earnings crush estimates as company raises guidance
Pfizer Inc.’s stock rose 3.2% early Tuesday, after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based drug company had net income of $4.465 billion,
Pfizer raises profit forecast after beating third-quarter estimates
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday. Shares of the U.S. drugmaker rose 3.
Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...
BioPharma Dive15h
Pfizer answers Starboard challenge with beat-and-raise quarter
Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...
FiercePharma14h
Pfizer bumps up revenue outlook by $1.5B in Paxlovid rebound amid criticism from activist investor Starboard
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer’s Hold Rating Maintained Amid Unsustainable Surprises and Limited Growth Prospects
Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...
Pfizer is getting another COVID-19 sales boost
Pfizer (PFE) reported its third-quarter earnings on Tuesday, beating Wall Street expectations and its raising its full-year ...
Pfizer’s Balanced Outlook: Hold Rating Amid Strong Q3 Results and Future Challenges
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00.
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Pfizer CEO Defends Turnaround Strategy as Activist Pressures Management
(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a ...